cabergoline has been researched along with Metabolic Syndrome in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auriemma, RS; Colao, A; Graziadio, C; Pirchio, R; Pivonello, R | 1 |
| Abucham, J; Correa-Silva, SR; Portari, LHC | 1 |
| Auriemma, RS; Colao, A; Galdiero, M; Gasperi, M; Giordano, C; Granieri, L; Mannarino, T; Negri, M; Perone, Y; Pivonello, C; Pivonello, R; Simeoli, C; Vitale, P | 1 |
| Barbosa, FR; Domingues, RC; dos Santos Silva, CM; Fontes, R; Gadelha, MR; Lima, GA; Warszawski, L | 1 |
1 review(s) available for cabergoline and Metabolic Syndrome
| Article | Year |
|---|---|
Metabolic effects of prolactin.
Topics: Bromocriptine; Cabergoline; Dopamine; Dopamine Agonists; Glucose; Humans; Hyperprolactinemia; Lipids; Male; Metabolic Syndrome; Obesity; Prolactin; Receptors, Dopamine; Receptors, Prolactin; Testosterone; Weight Gain | 2022 |
3 other study(ies) available for cabergoline and Metabolic Syndrome
| Article | Year |
|---|---|
Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study.
Topics: Adult; Cabergoline; Dopamine Agonists; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Middle Aged; Outcome Assessment, Health Care; Pilot Projects; Prolactin; Prolactinoma; Prospective Studies | 2022 |
Effect of cabergoline on metabolism in prolactinomas.
Topics: Adiposity; Adult; Antineoplastic Agents; Cabergoline; Dose-Response Relationship, Drug; Ergolines; Fasting; Female; Humans; Hyperprolactinemia; Insulin; Insulin Resistance; Male; Metabolic Diseases; Metabolic Syndrome; Pituitary Neoplasms; Prevalence; Prognosis; Prolactin; Prolactinoma; Prospective Studies; Time Factors; Treatment Outcome | 2013 |
BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
Topics: Adult; Aftercare; Aged; Blood Glucose; Body Composition; Body Mass Index; Body Weight; Bromocriptine; Cabergoline; Cholesterol, HDL; Cholesterol, LDL; Dopamine Agonists; Ergolines; Female; Humans; Insulin; Insulin Resistance; Leptin; Male; Metabolic Syndrome; Metabolome; Middle Aged; Obesity; Prevalence; Prolactinoma; Waist Circumference; Weight Gain; Young Adult | 2011 |